CCR3 inhibition for ocular angiogenesis and macular degeneration
View Patent ↗Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.
1. A method of inhibiting ocular angiogenesis comprising exposing a choroidal cell to a CCR3-inhibitory effective amount of an antibody which inhibits the activity of CCR3.
2. The method of claim 1 wherein the choroidal cell is a choroidal endothelial cell.
3. The method of claim 1 wherein exposing the choroidal cell to the antibody takes place in a mammal.
4. The method of claim 3 wherein the antibody is orally administered to the mammal.
5. The method of claim 3 wherein the antibody is intravenously administered to the mammal.
6. The method of claim 3 wherein the antibody is intraocularly injected into the mammal.
7. The method of claim 1 wherein the antibody is an antibody or antibody fragment which specifically binds CCR3 and thereby inhibits the activity of CCR3.
8. The method of claim 1 wherein the antibody is an antibody or antibody fragment which specifically binds eotaxin and thereby inhibits the activity of CCR3.
9. The method of claim 1 wherein the antibody is an antibody or antibody fragment which specifically binds eotaxin-2 and thereby inhibits the activity of CCR3.
10. The method of claim 1 wherein the antibody is an antibody or antibody fragment which specifically binds eotaxin-3 and thereby inhibits the activity of CCR3.
11. The method of claim 3 wherein the mammal is a human.